Search

Additional file 1: Table S1. Annual prevalence of nontuberculous mycobacterial pulmonary disease (NTM-PD) in Korea. Table S2. Annual incidence of nontuberculous mycobacterial pulmonary disease (NTM-PD) in female patients in the 20–59 age group (% difference).

Supplemental material, sj-pdf-1-ajs-10.1177_03635465211018636 for Allogenic Pure Platelet-Rich Plasma Therapy for Adhesive Capsulitis: A Bed-to-Bench Study With Propensity Score Matching Using a Corticosteroid Control Group by Min Ji Lee, Kang Sup Yoon, Sohee Oh, Sue Shin and Chris Hyunchul Jo in The American Journal of Sports Medicine

Supplementary_Table_S1 for Umbilical Cord Blood Units Cryopreserved in the Public Cord Blood Bank: A Breakthrough in iPSC Haplobanking? by Eun Youn Roh, Sohee Oh, Jong Hyun Yoon, Byoung Jae Kim, Eun Young Song and Sue Shin in Cell Transplantation

Supplemental material, DS_10.1177_0363546518800268 for Allogenic Pure Platelet-Rich Plasma Therapy for Rotator Cuff Disease: A Bench and Bed Study by Chris Hyunchul Jo, Seung Yeon Lee, Kang Sup Yoon, Sohee Oh and Sue Shin in The American Journal of Sports Medicine

Distribution of group A rotavirus G and P genotypes according to vaccination status, n (%) (DOCX 45 kb)

Distribution of group A rotavirus G and P genotypes according to the vaccination status (exclude incomplete vaccination cases, nâ =â 173) (DOCX 34 kb)

The importance of serum hepatitis B surface antigen (HBsAg) level as a surrogate marker for viral load and a predictor of treatment response remains unclear. The aim of this study was to investigate whether serum HBsAg correlates with serum hepatitis B virus (HBV) DNA during peginterferon (PEG-IFN) α-2a treatment (with or without thymosin α-1) in hepatitis B e antigen (HBeAg)-positive chronic hepatitis B patients and whether it can predict treatment response. Sera from 37 HBeAg-positive chronic hepatitis B patients receiving 48-weeks PEG-IFN α-2a with (n = 20) or without (n = 17) an initial 12-weeks thymosin α-1 were obtained at baseline and at weeks 12, 24, 36, 48 (end of treatment), 56, 72, 84, and 96 (end of follow-up). Taqman HBV DNA tests (Roche) and Architect HBsAg QT (Abbott) were performed. There was a moderate correlation between the HBsAg and HBV DNA levels (r = 0.452, P < 0.001). Median HBsAg levels at baseline and at week 96 were 6,218 IU/ml and 4,038 IU/ml, respectively. The mean HBV DNA and alanine aminotransferase (ALT) levels were 7.48 log(10) IU/ml and 173 IU/L at baseline and 5.37 log(10) IU/ml and 102 IU/L at week 96, respectively. A decrease to